Lifecore Biomedical, Inc. EBITDA for the Trailing 12 Months (TTM) ending February 23, 2025: USD -10.99 M

Lifecore Biomedical, Inc. EBITDA is USD -10.99 M for the Trailing 12 Months (TTM) ending February 23, 2025, a -63.80% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.
  • Lifecore Biomedical, Inc. EBITDA for the Trailing 12 Months (TTM) ending February 25, 2024 was USD -30.35 M, a -15.61% change year over year.
  • Lifecore Biomedical, Inc. EBITDA for the Trailing 12 Months (TTM) ending February 26, 2023 was USD -35.96 M, a 46.08% change year over year.
  • Lifecore Biomedical, Inc. EBITDA for the Trailing 12 Months (TTM) ending February 28, 2022 was USD -24.62 M, a -2.76% change year over year.
  • Lifecore Biomedical, Inc. EBITDA for the Trailing 12 Months (TTM) ending February 28, 2021 was USD -25.32 M, a 666.75% change year over year.
Key Data
Date EBITDA Net Income EPS (Diluted) Shares (Diluted, Weighted)